HEALTHx2: patient-centered approaches for studying the effectiveness and reproductive safety of antidepressant medication in perinatal women

The project augments observational data from the Norwegian Mother, Father, and Child Cohort Study (MoBa) linked to national registries, with genetic data in mother-father-child trios (MoBaGenetics) and novel biobank markers of mental illness (i.e., neurosteroids). The project is highly computational, and combines epidemiological methods for causal inference with Bayesian approach to polygenic risk scoring (i.e., LDpred2) and Mendelian Randomization Methods. The ultimate goal is to quantify antidepressant effectiveness in pregnant women, according to genetic variants of drug response, moving towards personalized medicine in the pregnant population. Similarly, our goal is to determine unbiased causal effects of prenatal antidepressant exposure on offspring metabolic risks later in life.